Entresto is protected by multiple patents, primarily covering its composition of matter and methods of use. These patents are crucial for Novartis, the manufacturer, to maintain market exclusivity for the drug. The patent landscape for Entresto is complex, with various patents having different expiration dates.
When does Entresto's main patent expire?
The foundational U.S. patent for Entresto, U.S. Patent No. 8,860,793, related to sacubitril/valsartan, was set to expire in November 2025 [1]. However, this date is subject to potential extensions and challenges.
Are there other patents protecting Entresto?
Yes, Entresto is protected by a portfolio of patents beyond the primary composition of matter patent. These can include patents on specific formulations, manufacturing processes, and methods of treatment. For instance, other patents related to Entresto have expiration dates extending into the 2030s [2]. DrugPatentWatch.com provides detailed information on these patents and their expiration timelines [2].
Can generic versions of Entresto be launched before patent expiry?
Generally, generic versions cannot be legally marketed in the U.S. before the expiration of relevant patents, unless those patents are successfully challenged or invalidated. The Hatch-Waxman Act provides a framework for generic drug approval, but it respects existing patent protections.
What happens if Entresto patents are challenged?
Patent challenges, often brought by generic drug manufacturers, can lead to the invalidation or shortening of patent terms. If Entresto's patents are successfully challenged and invalidated before their listed expiration dates, generic versions could potentially enter the market earlier. Litigation surrounding these patents is a common occurrence in the pharmaceutical industry.
How does Entresto's patent situation affect its price?
The patent protection for Entresto allows Novartis to sell the drug without direct competition, contributing to its current pricing. Once patents expire and generic versions become available, competition typically drives down prices significantly. Information on Entresto's pricing is available through various health and pharmaceutical cost resources.
Who are Entresto's competitors?
While Entresto is on patent, its primary competition comes from other medications used to treat heart failure. These include other classes of drugs that target different mechanisms in managing the condition. Once generics emerge, they will directly compete with the branded Entresto.
What is Entresto used for?
Entresto (sacubitril/valsartan) is a prescription medicine used to reduce the risk of death and hospitalization in people with chronic heart failure with reduced ejection fraction [1]. It works by blocking the body's attempt to break down beneficial hormones that help relax blood vessels and reduce salt and fluid load.